Savara (NASDAQ:SVRA) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Savara (NASDAQ:SVRA) from a hold rating to a sell rating in a research note released on Saturday.

A number of other brokerages have also recently weighed in on SVRA. Guggenheim restated a “buy” rating on shares of Savara in a report on Tuesday, December 23rd. HC Wainwright upped their price target on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. Oppenheimer set a $10.00 price objective on Savara in a research note on Tuesday, December 23rd. Finally, Wells Fargo & Company lifted their target price on Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

Savara Price Performance

Shares of NASDAQ SVRA opened at $5.25 on Friday. Savara has a twelve month low of $1.89 and a twelve month high of $7.01. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average of $5.67 and a two-hundred day moving average of $4.96. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -9.91 and a beta of 0.31.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after purchasing an additional 3,205 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after purchasing an additional 9,463 shares during the period. Xponance LLC purchased a new stake in shares of Savara in the fourth quarter valued at $66,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Savara in the third quarter valued at $44,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Savara in the second quarter worth $30,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.